Why the study?
This study aimed to examine the imaging findings of undifferentiated pleomorphic sarcoma and myxofibrosarcoma and identify a prognostic factor for recurrence.
Can imaging findings differentiate undifferentiated pleomorphic sarcoma from myxofibrosarcoma and predict recurrence?
Can imaging findings differentiate undifferentiated pleomorphic sarcoma from myxofibrosarcoma and predict recurrence?
Imaging characteristics such as T2 signal intensity, ADC value, CT attenuation, and SUVmax can differentiate UPS from MFS and predict recurrence.
OBJECTIVE: This study aimed to examine the imaging findings of undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) and identify a prognostic factor for recurrence. MATERIALS AND METHODS: F-fluorodeoxyglucose-PET/CT results were retrospectively examined and compared between the two diseases. RESULTS: /s, p < 0.01) were lower in UPS than in MFS. CT attenuation (37 vs. 22 Hounsfield Unit, p < 0.01) and maximum standardized uptake value (SUVmax) (15.6 vs. 5.2, p < 0.01) were greater in UPS than in MFS. Univariate analysis found that pathological diagnosis of UPS (hazard ratio: 15.6) and low or intermediate signal intensity on T2-weighted images (hazard ratio: 15.7) were predictors of recurrence. CONCLUSION: The signal intensity on T2-weighted images, ADC value, CT attenuation, and SUVmax were relevant imaging results for distinguishing UPS from MFS. The pathological diagnosis and signal intensity on T2-weighted images were prognostic indicators of recurrence.
No takes yet. Share an insight, caveat, or question.
Kawaguchi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: